Stock Detail
THRESHOLD PHARMACEUTICALS INC
Sector: Biotechnology
Latest Quote @ Thu Jun 6 05:23:04 (15 min delayed)
| $5.14 |
$5.50 |
$5.46 |
-0.04 |
-0.73% |
|
Last Day's Data
| $5.46 |
$5.58 |
$0.00 |
0.00% |
0.00 |
$5.50 |
| $5.51 |
$5.35 |
307,628.00 |
308.75M |
575,313.00 |
8.65 |
Pivot Table
| R2 |
R1 |
Pivot |
S1 |
S2 |
| 5.69 |
5.57 |
5.46 |
5.34 |
5.23 |
Stock Profile
Threshold Pharmaceuticals, Inc., a development stage company, engages in the discovery, development, and commercialization of small molecule therapeutics based on ‘Metabolic Targeting'. Metabolic Targeting is an approach that targets fundamental differences in metabolism between normal and diseased cells. The company focuses on the treatment of cancer and benign prostatic hyperplasia (BPH), a disease characterized by overgrowth of the prostate. Its three product candidates include glufosfamide, which in the Phase 3 clinical trial for the second-line treatment of pancreatic cancer; TH-070, another product candidate for the treatment of BPH, which is in Phase 2 clinical trial; and 2-Deoxyglucose, for the treatment of solid tumors. The company was founded by George F. Tidmarsh. Threshold Pharmaceuticals was incorporated in 2001 and is headquartered in Redwood City, California.
